Full Agenda

December 7-9, 2020

Task Force Meetings
(Task Force Members)

•  Review of New Resolutions

Thursday, December 10, 2020

BBA Meetings and Policy Sessions
(BBA Members Only)

• 1:00 PM EST BBA Meeting
• 1:45 PM EST BBA Elections 

POLICY SESSIONS
 - registration closed-

• 2:00 PM EST Welcome

• 2:00 PM EST  Police Accountability and Criminal Justice

Several tragedies have once more brought racial justice to the forefront of American political discourse. Actions of police officers in different jurisdictions, due to carelessness, bias, or outright racism, have led to calls of increasing police accountability, removing police from non-essential functions like school security to decrease potentially unnecessary criminal-justice interactions (known as defunding the police), enacting and enforcing policies to end profiling and stereotyping (including punishing the weaponization of stereotypes by those pressing charges or reporting potentially criminal activity), increasing minority community involvement in police practices and policies, demilitarizing police equipment and practices and, specifically, eliminating or greatly curbing the use of no-knock warrants. Prior to the well-known abuses starting in late spring, a growing bipartisan consensus also called for eliminating or curbing the use of civil asset forfeiture laws because of the unfairly skewed posture the asset holder is forced into when defending at court, subverting the principle of innocent until proven guilty. This session will discuss these policies and the strategies to enact them.

Moderator:
Representative Kerry Tipper (CO), Chair of Law and Criminal Justice Task Force, NHCSL
Participants:
Alex Vitale, Policing & Social Justice Project, Brooklyn College
Juan Cartagena, President and General Counsel, Latino Justice PRLDEF
Kate Chatfield, Director of Policy, The Justice Collaborative

• 2:58 PM EST Transition to next session

• 3:00 PM EST  Census 2020 Update and Redistricting

In October, the Supreme Court allowed the Trump administration to end the Decennial Census before everyone could be counted. While the Census Bureau website lists a 99.9% enumeration rate in all states and jurisdictions, only the Self-Response rate guarantees a high-confidence count, while the Nonresponse Follow-up enumeration rate only conveys that the Bureau has stopped trying to contact the household, not that residents were actually counted. Experts, including Census Bureau personnel, will discuss response rates and the consequences of the failure to achieve a complete count. Further, we will discuss redistricting strategies and concerns, as well as the status of litigation against the President’s memorandum calling for the exclusion of undocumented immigrants from the apportionment count.

Moderator:
Senator Daniel Ivey Soto (NM), President, NHCSL
Participants:
Wendy Underhill, Director of Elections and Redistricting, NCSL
Jorge L. Vasquez Jr., Program Director for Power and Democracy Program, Advancement Project
Assemblyman Robert Rodriguez (NY)
Representative Joe Moody (TX), Speaker Pro Tempore

• 3:43 PM EST Transition to next session

• 3:45 PM EST  Lilly Diabetes Solution Center Presentation 

As part of its efforts to help people with diabetes who suffered financially due to COVID-19, in April Lilly announced their Insulin Value Program that caps monthly expense of Lilly insulin to $35 for the uninsured and commercially insured regardless of income. In September, Lilly added this program to its on-going suite of suite of affordability options that will be available beyond the COVID-19 crisis. The card is accessible online and through the Lilly Diabetes Solution Center and covers most Lilly insulin products.  All of our programs are accessible in Spanish.   Separately, Lilly also announced its participation in the new Medicare part D Senior Savings Model which will also cap a senior’s monthly insulin expenses at $35.   This short session will help legislators understand the program so they are able to direct constituents on Lilly insulin who reach out for help to get its benefits.

Moderator:
Dr. Aliza Lifshitz, Editorial Director, Vida y Salud
Participant: 
Cynthia Cardona, Senior Advisor in Corporate Affairs, Eli Lilly and Company

Friday, December 11, 2020

NHCSL Annual Meeting
(Legislators and BBA Only)

• 1:00 PM – 2:30 PM EST Vote and Ratification of Resolutions

Thursday, December 17, 2020

3:00 PM EST   COVID-19 Treatments and Vaccine Rollout
You must register for this session » 

One of the most important milestones to return to normal after the COVID-19 pandemic is the development, approval and distribution of a vaccine. Both Pfizer (an NHCSL Business Board Member) and Moderna have requested emergency FDA authorization of 95%-effective vaccines they have developed. The Pfizer clinical trials actively sought to include people of color. Some vaccine candidates require extreme refrigeration at -70 degrees Celsius (-94o F), which will impact their distribution, and potentially require reformulation before widespread use. Priority vaccine distribution determinations are ongoing.

Equally important is the development, approval and availability of treatments. The world urgently needs medicines that can help reduce the impact of COVID-19 while the global scientific community works toward an eventual vaccine. Eli Lilly and Company (another NHCSL Business Board Member) is studying the world’s first therapies specifically designed to treat COVID-19 — antibodies engineered for their potential to neutralize, and potentially treat, the disease. In addition to antibodies, Lilly medicines are being studied to understand their potential in treating complications of COVID-19. And, they are engaging global regulators regarding emergency-use authorization (EUA) for these treatments, which was recently granted by the U.S. FDA for two different therapies. This session will discuss all those aspects of the ongoing pandemic as well as the human resources impact of vaccines and treatments.

Moderator:
Dr. Aliza Lifshitz, Editorial Director, Vida y Salud
Participants: 
Dr. Alejandro Cané, North America Chief of Scientific and Medical Affairs, Vaccines Division, Pfizer
Dr. Carlos O Garner, Vice President, Global Regulatory Affairs, Eli Lilly and Company
VADM Jerome M. Adams, M.D., M.P.H., U.S. Surgeon General